1. Home
  2. |Insights
  3. |Are Your GSA Schedule Products TAA-Compliant?

Are Your GSA Schedule Products TAA-Compliant?

Client Alert | less than 1 min read | 10.08.14

While Multiple Award Schedules administered by GSA can be a valuable tool for selling to government customers, these government-wide contracts include numerous special requirements, including the requirement that each and every product offered comply with the Trade Agreements Act restriction on providing products from so-called "non-designated countries." In "Where Are Your Products From? The Importance and Challenges of Managing TAA Compliance for GSA Schedule Holders", published in Bloomberg BNA Federal Contracts Report, C&M's Cathy Kunz and Addie Cliffe discuss recent enforcement actions that highlight the risk of TAA non-compliance and offer practical pointers for assuring compliance.


Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights